{"groups":[{"description":"Patients with HRD status unknown who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor genome-wide LOH was not tested or not determined were considered HRD unknown.","id":"FG000","title":"HRD Unknown"},{"description":"Patients with HRD status negative who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor had genome-wide LOH \\< 10% were considered HRD-negative.","id":"FG001","title":"HRD Negative"},{"description":"Patients with HRD status positive who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor had genome-wide LOH ≥ 10% were considered HRD-positive.","id":"FG002","title":"HRD Positive"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"47"},{"groupId":"FG001","numSubjects":"30"},{"groupId":"FG002","numSubjects":"20"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"47"},{"groupId":"FG001","numSubjects":"30"},{"groupId":"FG002","numSubjects":"20"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"97 subjects were recruited from 40 sites across 6 countries."}